MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal CancerResearch Question:
What is the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when
combined with MGA012? And what are the pharmacokinetics (PK), immunogenicity, pharmacodynamics
(PD), and the anti-tumor activity of the combination of MGD007 and MGA012?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This study is designed to characterize the safety, tolerability, pharmacokinetics,
pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of MGD007 and
MGA012, administered in combination by IV infusion, in patients with relapsed/refractory
metastatic colorectal carcinoma.
The study consists of a Dose Escalation Phase to determine the Maximum Tolerated Dose
(MTD) or Maximum Administered Dose (MAD) - MAD; if no MTD is defined - of the drug
combination, followed by a Cohort Expansion Phase to further define the safety and
initial anti-tumor activity of the drug combination with the doses established in
the Dose Escalation Phase.
Study Reference #: IGIC18049
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tanya Smith
Phone: (585) 275-8213
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search